Showing results (451-460 of 782) with videos related to
Sort By:
Pageof 79
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myelomaS Vincent Rajkumar, Paul G Richardson, Martha Q Lacy, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|October 15, 2014
Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivoJonathan D Ashley, Jared F Stefanick, Valerie A Schroeder, et al.Blood|November 21, 2024
Development of hyperdiploidy starts at an early age and takes a decade to completeMehmet K Samur, Anil Aktas Samur, Parth Shah, et al.Advanced Healthcare Materials|September 24, 2021
A 3D-Bioprinted Multiple Myeloma ModelDi Wu, Zongyi Wang, Jun Li, et al.British Journal of Haematology|November 7, 2008
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyStephanie J Lee, Paul G Richardson, Pieter Sonneveld, et al.Leukemia & Lymphoma|August 20, 2011
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myelomaDavid Siegel, Sundar Jagannath, David H Vesole, et al.Blood Cancer Discovery|February 4, 2026
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based CombinationsAnnamaria Gullà, Madhav V Dhodapkar, Hermann Einsele, et al.Blood|August 30, 2002
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cellsDharminder Chauhan, Laurence Catley, Teru Hideshima, et al.Cancer Research|July 3, 2004
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cellsPierfrancesco Tassone, Antonella Gozzini, Victor Goldmacher, et al.Pageof 79